

AUG 19 2002

#13

RECEIVER

AUG 21 1968

1-1-2002
TECH CENTER 1600/2900

INFORMATION DISCLOSURE CITATION	ATTY. DOCKET NO. 3764-2	SERIAL NO 09/508,195	RECEIVE AUG 21 2002
APPLICANT HARDERN et al		GROUP	TECH CENTER 1600/29
(Use several sheets if necessary)		FILING DATE March 8, 2000	1624

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

A. David Rodrigues; Commentary, "Use of *In Vitro* Human Metabolism Studies in Drug Development; Biochemical Pharmacology", Vol. 48, No. 12, pp. 2147-2156, 1994.

Mistry, et al; "Glucuronidation *In Vitro* and *In Vivo* Comparison of Intestinal and Hepatic Conjugation of Morphine, Naloxone, and Buprenorphine; The American Society for Pharmacology and Experimental Therapeutics", Vol. 15, No. 5, pp. 710-717; 1987.

J. Brian Houston; Commentary, "Utility of *In Vitro* Drug Metabolism Data in Predicting *In Vivo* Metabolic Clearance; Biochemical Pharmacology", Vol. 47, No. 9, pp. 1469-1479, 1994.

Martindale Thirty-third edition; "The Complete Drug Reference"; Pharmaceutical Press; pp. 1086-1089.

Awni, et al; "The Effect of Mild or Moderate Hepatic Impairment (Cirrhosis) on the Pharmacokinetics of Zileuton"; Clin. Pharmacokinet, 29 (Suppl. 2): 49-61, 1995.

*Examiner

Date Considered

9-11-2002

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)